DB:C6O

Stock Analysis Report

Executive Summary

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally.

Snowflake

Fundamentals

Limited growth with questionable track record.


Similar Companies

Share Price & News

How has Clovis Oncology's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: C6O's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

49.3%

C6O

-1.6%

DE Biotechs

0.8%

DE Market


1 Year Return

-58.9%

C6O

-8.9%

DE Biotechs

9.0%

DE Market

Return vs Industry: C6O underperformed the German Biotechs industry which returned -8.9% over the past year.

Return vs Market: C6O underperformed the German Market which returned 9% over the past year.


Shareholder returns

C6OIndustryMarket
7 Day49.3%-1.6%0.8%
30 Day74.2%-1.5%6.3%
90 Day3.9%-8.3%14.4%
1 Year-58.9%-58.9%-8.7%-8.9%12.4%9.0%
3 Year-83.9%-83.9%49.7%47.8%25.6%14.5%
5 Year-87.6%-87.6%-1.5%-4.6%41.0%21.8%

Price Volatility Vs. Market

How volatile is Clovis Oncology's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Clovis Oncology undervalued compared to its fair value and its price relative to the market?


Share Price vs. Fair Value

Below Fair Value: C6O (€5.19) is trading above our estimate of fair value (€4.13)

Significantly Below Fair Value: C6O is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: C6O is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: C6O is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate C6O's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: C6O has negative assets, so we can't compare its PB Ratio to the DE Biotechs industry average.


Next Steps

Future Growth

How is Clovis Oncology forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

44.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: C6O is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: C6O is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: C6O is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: C6O's revenue (35.8% per year) is forecast to grow faster than the German market (4.9% per year).

High Growth Revenue: C6O's revenue (35.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if C6O's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Clovis Oncology performed over the past 5 years?

-10.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: C6O has high quality earnings.

Growing Profit Margin: C6O's current net profit margins (-298.5%) are higher than last year (-390.6%).


Past Earnings Growth Analysis

Earnings Trend: C6O is unprofitable, and losses have increased over the past 5 years at a rate of -10.8% per year.

Accelerating Growth: Unable to compare C6O's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: C6O is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).


Return on Equity

High ROE: C6O's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Clovis Oncology's financial position?


Financial Position Analysis

Short Term Liabilities: C6O has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: C6O has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: C6O has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: C6O's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: C6O has a low level of unsold assets or inventory.

Debt Coverage by Assets: C6O has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: C6O has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: C6O has sufficient cash runway for 1.304022 years if free cash flow continues to reduce at historical rates of -17.1% each year.


Next Steps

Dividend

What is Clovis Oncology's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage1.1%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate C6O's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate C6O's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if C6O's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if C6O's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of C6O's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of Clovis Oncology's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Patrick Mahaffy (56yo)

10.6yrs

Tenure

US$6,267,458

Compensation

Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. on April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic ...


CEO Compensation Analysis

Compensation vs Market: Patrick's total compensation ($USD6.27M) is above average for companies of similar size in the German market ($USD511.20K).

Compensation vs Earnings: Patrick's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.8yrs

Average Tenure

55yo

Average Age

Experienced Management: C6O's management team is considered experienced (3.8 years average tenure).


Board Age and Tenure

10.6yrs

Average Tenure

63yo

Average Age

Experienced Board: C6O's board of directors are seasoned and experienced ( 10.6 years average tenure).


Insider Trading

Insider Buying: C6O insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$210,45721 Aug 19
James Blair
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares40,000
Max PriceUS$5.38
BuyUS$251,95419 Aug 19
Patrick Mahaffy
EntityIndividual
Role
Chief Executive Officer
Co-Founder
Shares50,000
Max PriceUS$5.06
BuyUS$43,94416 Aug 19
Thorlef Spickschen
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares8,600
Max PriceUS$5.11
BuyUS$45,07815 Aug 19
Thorlef Spickschen
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares9,200
Max PriceUS$4.90
SellUS$419,38318 Mar 19
Domain Associates, L.L.C.
EntityCompany
Shares17,056
Max PriceUS$24.59
BuyUS$47,77408 Mar 19
Armistice Capital LLC
EntityCompany
Shares1,920
Max PriceUS$24.88
SellUS$1,465,42908 Mar 19
Armistice Capital LLC
EntityCompany
Shares2,240,920
Max PriceUS$28.39

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.8%.


Management Team

  • Dan Muehl (55yo)

    Executive VP & CFO

    • Tenure: 3.7yrs
    • Compensation: US$1.51m
  • Patrick Mahaffy (56yo)

    Co-Founder

    • Tenure: 10.6yrs
    • Compensation: US$6.27m
  • Gillian Ivers-Read (65yo)

    Co-Founder

    • Tenure: 10.6yrs
    • Compensation: US$1.76m
  • Anna Sussman

    Vice President of Investor Relations

    • Tenure: 0yrs
  • Paul Gross (54yo)

    Chief Compliance Officer

    • Tenure: 3.8yrs
  • Ann Bozeman

    Executive Vice President of Human Resources

    • Tenure: 3.2yrs
  • Breanna Burkart

    Vice President of Investor Relations & Corporate Communications

    • Tenure: 3.2yrs
  • Lindsey Rolfe (51yo)

    Executive VP of Clinical

    • Tenure: 4.3yrs
    • Compensation: US$1.82m

Board Members

  • Paul Klingenstein (63yo)

    Independent Director

    • Tenure: 10.6yrs
    • Compensation: US$359.98k
  • Brian Atwood (66yo)

    Independent Director

    • Tenure: 10.8yrs
    • Compensation: US$364.98k
  • Ed McKinley (67yo)

    Independent Director

    • Tenure: 10.8yrs
    • Compensation: US$369.98k
  • Jim Blair (79yo)

    Independent Director

    • Tenure: 10.8yrs
    • Compensation: US$369.98k
  • Ginger Graham (63yo)

    Chairman

    • Tenure: 0.4yrs
    • Compensation: US$357.48k
  • Patrick Mahaffy (56yo)

    Co-Founder

    • Tenure: 10.6yrs
    • Compensation: US$6.27m
  • Thorlef Spickschen (78yo)

    Independent Director

    • Tenure: 10.8yrs
    • Compensation: US$357.48k
  • Keith Flaherty (48yo)

    Independent Director

    • Tenure: 6.8yrs
    • Compensation: US$354.98k
  • Rick Fair (50yo)

    Independent Director

    • Tenure: 1.1yrs
    • Compensation: US$539.35k
  • Bob Azelby (51yo)

    Independent Director

    • Tenure: 1.1yrs
    • Compensation: US$538.72k

Company Information

Clovis Oncology, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clovis Oncology, Inc.
  • Ticker: C6O
  • Exchange: DB
  • Founded: 2009
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$294.906m
  • Listing Market Cap: US$267.774m
  • Shares outstanding: 54.82m
  • Website: https://www.clovisoncology.com

Number of Employees


Location

  • Clovis Oncology, Inc.
  • 5500 Flatiron Parkway
  • Suite 100
  • Boulder
  • Colorado
  • 80301
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLVSNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDNov 2011
C6ODB (Deutsche Boerse AG)YesCommon StockDEEURNov 2011

Biography

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, the European Union, and internationally. The company offer ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/12 21:21
End of Day Share Price2019/11/12 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.